Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 3
2020 2
2021 5
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: maesaka f. Cancers (Basel). 2022 Mar 29;14(7):1735. doi: 10.3390/cancers14071735. Cancers (Basel). 2022. PMID: 35406508 Free PMC article.
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
Nishimura N, Miyake M, Shimizu T, Matsubara T, Miyamoto T, Sakamoto K, Yamada A, Matsumoto Y, Yoshikawa M, Ichikawa K, Omori C, Maesaka F, Oda Y, Kiba K, Tomioka A, Hosokawa Y, Tanaka M, Otani T, Fujimoto K. Nishimura N, et al. Among authors: maesaka f. Int J Clin Oncol. 2022 Nov;27(11):1733-1741. doi: 10.1007/s10147-022-02230-9. Epub 2022 Aug 27. Int J Clin Oncol. 2022. PMID: 36029377
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F, Oda Y, Tachibana A, Tomizawa M, Ohmori C, Matsumura Y, Ichikawa K, Mizobuchi S, Yoshikawa T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: maesaka f. Clin Genitourin Cancer. 2022 Apr;20(2):196.e1-196.e9. doi: 10.1016/j.clgc.2021.11.006. Epub 2021 Nov 15. Clin Genitourin Cancer. 2022. PMID: 34916166
16 results